#semaglutide

Researchers traced semaglutide’s activity inside appetite-regulating neurons and found a molecular mechanism that may explain both strong responses and eventual plateaus.

New tracking from EPIC Research suggests rapid growth in GLP-1 prescribing has coincided with a small but sustained drop in obesity rates across a large medical-records dataset.

Researchers at Ben-Gurion University say semaglutide and colchicine protect the heart through different mechanisms after injury, offering a clearer picture of how existing drugs might help prevent atrial fibrillation

A study published in JAMA Psychiatry found that semaglutide significantly improved measures of motivation in patients with major depressive disorder, pointing to a potentially important new line of investigation beyond a

A new paper has linked Wegovy to ischemic optic neuropathy, sometimes called an eye stroke, but experts say the evidence is preliminary and the overall rate reported so far remains very low.

A new study cited by Endpoints suggests Eli Lilly’s tirzepatide may produce greater lean body mass loss than Novo Nordisk’s semaglutide, even as tirzepatide drives more overall weight reduction.

A prespecified analysis of the SELECT trial found semaglutide reduced major adverse cardiovascular events in patients at elevated risk of substantial liver fibrosis while also lowering fatty liver index versus placebo.

Two phase 3 EVOKE(+) trials found that semaglutide did not slow clinical progression in Alzheimer’s disease, despite earlier signals that GLP-1 drugs might help.